English
Insider transactions
EDGARLyell Immunopharma, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-19.
- Open-market purchases (code P)
- 4 transactions, 5,618,704 shares
- Sum of shares × price per share: 74,999,953.28
- Open-market sales (code S)
- 29 transactions, 31,569 shares
- Sum of shares × price per share: 612,747.03
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 55
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-10 Filed 2026-11-12 | Lee Gary K. Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 129 | 15.93 | 2,054.97Derived: shares × price per share. Exact value 2054.97. | 16,091 | Direct (D) | No | F1
| Open filing 0001907345-26-000008 Read from the filing’s XML Dispute this row |
| 2026-11-10 Filed 2026-11-12 | Bulis Veronica Sanchez Officer: VP, Corporate Controller | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 416 | 15.93 | 6,626.88Derived: shares × price per share. Exact value 6626.88. | 14,383 | Direct (D) | No | F1
| Open filing 0002095702-26-000007 Read from the filing’s XML Dispute this row |
| 2026-11-10 Filed 2026-11-12 | Hill Stephen J. Officer: Chief Operating Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 88 | 15.93 | 1,401.84Derived: shares × price per share. Exact value 1401.84. | 16,728 | Direct (D) | No | F1
| Open filing 0001866154-26-000008 Read from the filing’s XML Dispute this row |
| 2026-11-10 Filed 2026-11-12 | Seely Lynn Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 545 | 15.93 | 8,681.85Derived: shares × price per share. Exact value 8681.85. | 63,354 | Direct (D) | No | F1
| Open filing 0001327111-26-000008 Read from the filing’s XML Dispute this row |
| 2026-11-04 Filed 2026-11-05 | ARCH Venture Fund XIII, L.P. 10% ownerARCH Venture Partners XIII, L.P. 10% ownerARCH Venture Partners XIII, LLC 10% ownerCRANDELL KEITH 10% ownerGILLIS STEVEN 10% ownerNELSEN ROBERT 10% ownerBurow Kristina 10% ownerBERNS PAUL L 10% ownerBYBEE CLINTON 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 2,321,262 | 10.77 | 24,999,991.74Derived: shares × price per share. Exact value 24999991.74. | 3,747,790 | Indirect (I) See Footnote | No | F1, F2
| Open filing 0001012975-26-001013 Read from the filing’s XML Dispute this row |
| 2026-11-04 Filed 2026-11-05 | ARCH Venture Partners IX, LLC 10% ownerARCH Venture Fund IX, L.P. 10% ownerARCH Venture Partners IX, L.P. 10% ownerARCH Venture Fund IX Overage, L.P. 10% ownerARCH Venture Partners IX Overage, L.P. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 2,321,262 | 10.77 | 24,999,991.74Derived: shares × price per share. Exact value 24999991.74. | 3,747,790 | Indirect (I) See Footnote | No | F1, F2
| Open filing 0001012975-26-001014 Read from the filing’s XML Dispute this row |
| 2026-10-12 Filed 2026-10-13 | Aguirre Jarrad Mattieu Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 422 | 8.63 | 3,641.86Derived: shares × price per share. Exact value 3641.86. | 19,857 | Direct (D) | No | F1, F2
| Open filing 0002150331-26-000003 Read from the filing’s XML Dispute this row |
| 2026-09-10 Filed 2026-09-10 | Aguirre Jarrad Mattieu Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 47,500 | 0 | — | 47,500 | Direct (D) | No | F2
| Open filing 0002150331-26-000002 Read from the filing’s XML Dispute this row |
| 2026-09-10 Filed 2026-09-10 | Shook David Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 500 | 12.70 | 6,350Derived: shares × price per share. Exact value 6350.00. | 20,423 | Direct (D) | No | F1, F2
| Open filing 0001959742-26-000003 Read from the filing’s XML Dispute this row |
| 2026-08-21 Filed 2026-08-25 | Hill Stephen J. Officer: Chief Operating Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 989 | 15.54 | 15,369.06Derived: shares × price per share. Exact value 15369.06. | 16,816 | Direct (D) | No | F1
| Open filing 0001866154-26-000006 Read from the filing’s XML Dispute this row |
| 2026-08-21 Filed 2026-08-25 | Lee Gary K. Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,457 | 15.54 | 22,641.78Derived: shares × price per share. Exact value 22641.78. | 16,220 | Direct (D) | No | F1
| Open filing 0001907345-26-000006 Read from the filing’s XML Dispute this row |
| 2026-08-21 Filed 2026-08-25 | Seely Lynn Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 9,589 | 15.54 | 149,013.06Derived: shares × price per share. Exact value 149013.06. | 63,899 | Direct (D) | No | F1
| Open filing 0001327111-26-000006 Read from the filing’s XML Dispute this row |
| 2026-08-10 Filed 2026-08-11 | Lee Gary K. Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 131 | 14.34 | 1,878.54Derived: shares × price per share. Exact value 1878.54. | 17,677 | Direct (D) | No | F1, F2
| Open filing 0001907345-26-000004 Read from the filing’s XML Dispute this row |
| 2026-08-10 Filed 2026-08-11 | Bulis Veronica Sanchez Officer: VP, Corporate Controller | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 621 | 14.34 | 8,905.14Derived: shares × price per share. Exact value 8905.14. | 14,799 | Direct (D) | No | F1, F2
| Open filing 0002095702-26-000005 Read from the filing’s XML Dispute this row |
| 2026-08-10 Filed 2026-08-11 | Hill Stephen J. Officer: Chief Operating Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 89 | 14.34 | 1,276.26Derived: shares × price per share. Exact value 1276.26. | 17,805 | Direct (D) | No | F1, F2
| Open filing 0001866154-26-000004 Read from the filing’s XML Dispute this row |
| 2026-08-10 Filed 2026-08-11 | Seely Lynn Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 390 | 14.34 | 5,592.6Derived: shares × price per share. Exact value 5592.60. | 73,488 | Direct (D) | No | F1, F2
| Open filing 0001327111-26-000004 Read from the filing’s XML Dispute this row |
| 2026-07-27 Filed 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | JOther acquisition or disposition (describe transaction) | Disposed (D) | 44,000 | 0 | — | 2,774,980 | Direct (D) | No | F1, F2
| Open filing 0001140361-26-029817 Read from the filing’s XML Dispute this row |
| 2026-07-27 Filed 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | JOther acquisition or disposition (describe transaction) | Disposed (D) | 38,500 | 0 | — | 2,818,980 | Direct (D) | No | F1, F2
| Open filing 0001140361-26-029791 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-20 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 10 | 13.7 | 137Derived: shares × price per share. Exact value 137.0. | 2,857,480 | Direct (D) | Yes | F1
| Open filing 0001140361-26-028955 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 10 | 13.73 | 137.3Derived: shares × price per share. Exact value 137.30. | 2,857,490 | Direct (D) | Yes | F1
| Open filing 0001140361-26-028846 Read from the filing’s XML Dispute this row |
| 2026-06-29 Filed 2026-07-01 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | JOther acquisition or disposition (describe transaction) | Disposed (D) | 76,000 | 0 | — | 2,857,500 | Direct (D) | No | F1, F2
| Open filing 0001140361-26-027140 Read from the filing’s XML Dispute this row |
| 2026-06-15 Filed 2026-06-18 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | JOther acquisition or disposition (describe transaction) | Disposed (D) | 66,500 | 0 | — | 2,933,500 | Direct (D) | No | F1, F2
| Open filing 0001140361-26-025796 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-12 | Ramachandra Sumant Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,250 | 0 | — | 9,250 | Direct (D) | No | F3
| Open filing 0001439368-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-12 | BRAWLEY OTIS W Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,250 | 0 | — | 9,250 | Direct (D) | No | F2
| Open filing 0001213029-26-000007 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-12 | RIEFLIN WILLIAM JL Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,250 | 0 | — | 9,250 | Direct (D) | No | F1
| Open filing 0001182471-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-12 | FRIEDMAN CATHY Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,250 | 0 | — | 9,250 | Direct (D) | No | F4
| Open filing 0001411874-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-12 | Bachleda Mark Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,250 | 0 | — | 9,250 | Direct (D) | No | F1
| Open filing 0001887762-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-12 | NABEL ELIZABETH G Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,250 | 0 | — | 9,250 | Direct (D) | No | F1
| Open filing 0001619929-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-12 | Klausner Richard Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,250 | 0 | — | 9,250 | Direct (D) | No | F3
| Open filing 0001591178-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-11 | Shook David Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,977 | 12.64 | 24,989.28Derived: shares × price per share. Exact value 24989.28. | 20,923 | Direct (D) | No | F1, F2
| Open filing 0001959742-26-000002 Read from the filing’s XML Dispute this row |
| 2026-05-11 Filed 2026-06-15 | Bulis Veronica Sanchez Officer: VP, Corporate Controller | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 217 | 18.91 | 4,103.47Derived: shares × price per share. Exact value 4103.47. | 15,420 | Direct (D) | No | F1, F2
| Open filing 0002095702-26-000004 Read from the filing’s XML Dispute this row |
| 2026-05-11 Filed 2026-06-15 | Seely Lynn Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 388 | 18.91 | 7,337.08Derived: shares × price per share. Exact value 7337.08. | 73,878 | Direct (D) | No | F1, F2
| Open filing 0001327111-26-000003 Read from the filing’s XML Dispute this row |
| 2026-05-11 Filed 2026-06-15 | Lee Gary K. Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 130 | 18.92 | 2,459.6Derived: shares × price per share. Exact value 2459.60. | 17,808 | Direct (D) | No | F1, F2, F3
| Open filing 0001907345-26-000003 Read from the filing’s XML Dispute this row |
| 2026-05-11 Filed 2026-06-15 | Hill Stephen J. Officer: Chief Operating Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 89 | 18.92 | 1,683.88Derived: shares × price per share. Exact value 1683.88. | 17,894 | Direct (D) | No | F1, F2, F3
| Open filing 0001866154-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-09 Filed 2026-03-16 | Shah Smital Officer: Chief Fin. and Bus. Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 140,000 | 0 | — | 140,000 | Direct (D) | No | F1
| Open filing 0001808821-26-000006 Read from the filing’s XML Dispute this row |
| 2026-03-06 Filed 2026-03-09 | ARCH Venture Partners IX, LLC 10% ownerARCH Venture Partners IX, L.P. 10% ownerARCH Venture Partners IX Overage, L.P. 10% ownerARCH Venture Fund IX, L.P. 10% ownerARCH Venture Fund IX Overage, L.P. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 488,090 | 25.61 | 12,499,984.9Derived: shares × price per share. Exact value 12499984.90. | 1,426,528 | Indirect (I) See footnote | No | F1
| Open filing 0001012975-26-000235 Read from the filing’s XML Dispute this row |
| 2026-03-06 Filed 2026-03-09 | ARCH Venture Fund XIII, L.P. 10% ownerARCH Venture Partners XIII, L.P. 10% ownerARCH Venture Partners XIII, LLC 10% ownerCRANDELL KEITH 10% ownerNELSEN ROBERT 10% ownerBurow Kristina 10% ownerGILLIS STEVEN 10% ownerBERNS PAUL L 10% ownerBYBEE CLINTON 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 488,090 | 25.61 | 12,499,984.9Derived: shares × price per share. Exact value 12499984.90. | 1,426,528 | Indirect (I) See footnote | No | F1
| Open filing 0001012975-26-000234 Read from the filing’s XML Dispute this row |
| 2026-02-11 Filed 2026-02-12 | Hill Stephen J. Officer: Chief Operating Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,236 | 23.39 | 28,910.04Derived: shares × price per share. Exact value 28910.04. | 17,795 | Direct (D) | No | F1, F2
| Open filing 0001866154-26-000002 Read from the filing’s XML Dispute this row |
| 2026-02-11 Filed 2026-02-12 | Lee Gary K. Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,671 | 23.39 | 39,084.69Derived: shares × price per share. Exact value 39084.69. | 16,938 | Direct (D) | No | F1, F2
| Open filing 0001907345-26-000002 Read from the filing’s XML Dispute this row |
| 2026-02-11 Filed 2026-02-12 | Seely Lynn Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 7,455 | 23.39 | 174,372.45Derived: shares × price per share. Exact value 174372.45. | 74,266 | Direct (D) | No | F1, F2
| Open filing 0001327111-26-000002 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Lee Gary K. Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 147 | 23.12 | 3,398.64Derived: shares × price per share. Exact value 3398.64. | 18,609 | Direct (D) | No | F3
| Open filing 0001907345-26-000001 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Lee Gary K. Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000 | 0 | — | 50,000 | Direct (D) | No | F4
| Open filing 0001907345-26-000001 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Seely Lynn Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 438 | 23.12 | 10,126.56Derived: shares × price per share. Exact value 10126.56. | 81,721 | Direct (D) | No | F2
| Open filing 0001327111-26-000001 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Seely Lynn Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 155,000 | 0 | — | 155,000 | Direct (D) | No | F3
| Open filing 0001327111-26-000001 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Bulis Veronica Sanchez Officer: VP, Corporate Controller | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 8,750 | 0 | — | 15,891 | Direct (D) | No | F1
| Open filing 0002095702-26-000002 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Bulis Veronica Sanchez Officer: VP, Corporate Controller | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 254 | 23.12 | 5,872.48Derived: shares × price per share. Exact value 5872.48. | 15,637 | Direct (D) | No | F2
| Open filing 0002095702-26-000002 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Meltz Mark A Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000 | 0 | — | 50,000 | Direct (D) | No | F1
| Open filing 0001771329-26-000001 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Shook David Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000 | 0 | — | 50,000 | Direct (D) | No | F1
| Open filing 0001959742-26-000001 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Hill Stephen J. Officer: Chief Operating Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 109 | 23.12 | 2,520.08Derived: shares × price per share. Exact value 2520.08. | 19,031 | Direct (D) | No | F3
| Open filing 0001866154-26-000001 Read from the filing’s XML Dispute this row |
| 2026-02-10 Filed 2026-02-11 | Hill Stephen J. Officer: Chief Operating Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000 | 0 | — | 65,000 | Direct (D) | No | F4
| Open filing 0001866154-26-000001 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.
Showing 1–50 of 111
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| ARCH Venture Management, LLC | 3,247,162 SH | 31,789,716 dollars | Unchanged Prior quarter: 3,247,162 | Open filing 0001012975-26-001080 Filed 2026-11-16 Dispute this row |
| GSK plc | 1,512,659 SH | 14,808,932 dollars | Unchanged Prior quarter: 1,512,659 | Open filing 0001999371-26-024635 Filed 2026-11-05 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 799,057 SH | 7,822,767 dollars | Higher by 74,715 Prior quarter: 724,342 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| Orland Properties Ltd Partly reported under another manager | 754,698 SH | 7,388,493 dollars | Unchanged Prior quarter: 754,698 | Open filing 0001193125-26-460134 Filed 2026-11-13 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 748,848 SH | 7,331,222 dollars | Lower by 37,926 Prior quarter: 786,774 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| Decheng Capital LLC | 692,050 SH | 6,775,170 dollars | Unchanged Prior quarter: 692,050 | Open filing 0001104659-26-127247 Filed 2026-11-13 Dispute this row |
| Almitas Capital LLC | 448,130 SH | 4,387,193 dollars | Lower by 133,277 Prior quarter: 581,407 | Open filing 0002073679-26-000181 Filed 2026-11-17 Dispute this row |
| AQR CAPITAL MANAGEMENT LLC Partly reported under another manager | 345,922 SH | 3,386,576 dollars | Not in the prior quarter’s filings read | Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row |
| venBio Partners LLC | 337,697 SH | 3,306,054 dollars | Unchanged Prior quarter: 337,697 | Open filing 0000905148-26-004927 Filed 2026-11-16 Dispute this row |
| Alphabet Inc. Partly reported under another manager | 293,256 SH | 2,870,976 dollars | Unchanged Prior quarter: 293,256 | Open filing 0001652044-26-000086 Filed 2026-11-06 Dispute this row |
| Opaleye Management Inc. | 291,353 SH | 2,852,346 dollars | Lower by 52,672 Prior quarter: 344,025 | Open filing 0001420506-26-002880 Filed 2026-11-16 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 274,598 SH | 2,689,337 dollars | Lower by 36,038 Prior quarter: 310,636 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| JANE STREET GROUP, LLC Option: Put Partly reported under another manager | 219,800 SH | 2,151,842 dollars | Not in the prior quarter’s filings read | Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 191,807 SH | 1,877,791 dollars | Higher by 6,485 Prior quarter: 185,322 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager | 189,122 SH | 1,851,504 dollars | Higher by 58,932 Prior quarter: 130,190 | Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 168,122 SH | 1,645,914 dollars | Higher by 115,195 Prior quarter: 52,927 | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| HSG Holding Ltd Partly reported under another manager | 152,299 SH | 1,491,007 dollars | Unchanged Prior quarter: 152,299 | Open filing 0001193125-26-459331 Filed 2026-11-13 Dispute this row |
| Qube Research Technologies Ltd | 142,401 SH | 1,394,106 dollars | Higher by 31,870 Prior quarter: 110,531 | Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row |
| MILLENNIUM MANAGEMENT LLC | 141,059 SH | 1,380,968 dollars | Lower by 226,414 Prior quarter: 367,473 | Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row |
| GOLDMAN SACHS GROUP INC Partly reported under another manager | 108,541 SH | 1,062,616 dollars | Higher by 21,762 Prior quarter: 86,779 | Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row |
| CITADEL ADVISORS LLC Partly reported under another manager | 106,744 SH | 1,045,024 dollars | Higher by 88,049 Prior quarter: 18,695 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 98,662 SH | 965,900 dollars | Lower by 19,838 Prior quarter: 118,500 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager | 97,951 SH | 953 dollars | Higher by 38,203 Prior quarter: 59,748 | Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 93,149 SH | 911,929 dollars | Lower by 14,421 Prior quarter: 107,570 | Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 89,423 SH | 875,451 dollars | Higher by 52,373 Prior quarter: 37,050 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| MIC Capital Management UK LLP | 87,028 SH | 852,004 dollars | Unchanged Prior quarter: 87,028 | Open filing 0001889830-26-000006 Filed 2026-11-13 Dispute this row |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 86,227 SH | 844,162 dollars | Lower by 5,664 Prior quarter: 91,891 | Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row |
| Parkman Healthcare Partners LLC | 85,758 SH | 839,571 dollars | Not in the prior quarter’s filings read | Open filing 0001420506-26-002809 Filed 2026-11-16 Dispute this row |
| UBS Group AG Partly reported under another manager | 84,141 SH | 823,740 dollars | Higher by 58,159 Prior quarter: 25,982 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 76,187 SH | 745,871 dollars | Lower by 16,908 Prior quarter: 93,095 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| Trexquant Investment LP Partly reported under another manager | 67,175 SH | 657,643 dollars | Not in the prior quarter’s filings read | Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row |
| XTX Topco Ltd Partly reported under another manager | 57,903 SH | 566,870 dollars | Not in the prior quarter’s filings read | Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row |
| Point72 Asset Management, L.P. | 56,992 SH | 557,952 dollars | Higher by 30,912 Prior quarter: 26,080 | Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row |
| JPMORGAN CHASE CO Partly reported under another manager | 49,608 SH | 477,725 dollars | Higher by 44,812 Prior quarter: 4,796 | Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row |
| DIMENSIONAL FUND ADVISORS LP Partly reported under another manager | 46,434 SH | 454,248 dollars | Lower by 21,881 Prior quarter: 68,315 | Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row |
| Ikarian Capital, LLC | 41,081 SH | 402,183 dollars | Unchanged Prior quarter: 41,081 | Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row |
| CITADEL ADVISORS LLC Option: Put Partly reported under another manager | 39,400 SH | 385,726 dollars | Higher by 21,500 Prior quarter: 17,900 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| Squarepoint Ops LLC Partly reported under another manager | 39,044 SH | 382,241 dollars | Lower by 3,278 Prior quarter: 42,322 | Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row |
| Schonfeld Strategic Advisors LLC | 38,956 SH | 381,378 dollars | Not in the prior quarter’s filings read | Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row |
| GSA CAPITAL PARTNERS LLP | 38,400 SH | 376 dollars | Higher by 12,175 Prior quarter: 26,225 | Open filing 0001362033-26-000013 Filed 2026-11-16 Dispute this row |
| JANE STREET GROUP, LLC Partly reported under another manager | 36,452 SH | 356,865 dollars | Lower by 9,559 Prior quarter: 46,011 | Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row |
| Verdad Advisers, LP | 35,087 SH | 343,502 dollars | Not in the prior quarter’s filings read | Open filing 0001420506-26-002833 Filed 2026-11-16 Dispute this row |
| PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager | 30,657 SH | 301 dollars | Unchanged Prior quarter: 30,657 | Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row |
| CANADA PENSION PLAN INVESTMENT BOARD | 29,411 SH | 287,934 dollars | Unchanged Prior quarter: 29,411 | Open filing 0001104659-26-128255 Filed 2026-11-16 Dispute this row |
| RHUMBLINE ADVISERS | 25,787 SH | 252,446 dollars | Higher by 10,325 Prior quarter: 15,462 | Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row |
| BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager | 25,411 SH | 248,774 dollars | Higher by 17,566 Prior quarter: 7,845 | Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row |
| Empowered Funds, LLC Partly reported under another manager | 25,171 SH | 246,424 dollars | Not in the prior quarter’s filings read | Open filing 0001592828-26-000008 Filed 2026-11-13 Dispute this row |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 25,171 SH | 246,424 dollars | Higher by 7,171 Prior quarter: 18,000 | Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row |
| CITADEL ADVISORS LLC Option: Call Partly reported under another manager | 24,900 SH | 243,771 dollars | Higher by 7,900 Prior quarter: 17,000 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| Bank of New York Mellon Corp Partly reported under another manager | 24,818 SH | 242,969 dollars | Higher by 145 Prior quarter: 24,673 | Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Foresite Capital Management V, LLC 476,386 SH
- Sixth Street Partners Management Company, L.P. 107,570 SH
- HRT FINANCIAL LP 36,575 SH
- SUSQUEHANNA INTERNATIONAL GROUP, LLP 25,900 SH
- EntryPoint Capital, LLC 19,410 SH
- SUSQUEHANNA INTERNATIONAL GROUP, LLP 14,200 SH
- Graham Capital Management, L.P. 11,602 SH
- Brevan Howard Capital Management LP 11,557 SH
- Walleye Capital LLC 10,451 SH
- LOS ANGELES CAPITAL MANAGEMENT LLC 9,505 SH
- Truvestments Capital LLC 300 SH
- GROUP ONE TRADING LLC 100 SH
- GROUP ONE TRADING LLC 88 SH
- Optiver Holding B.V. 20 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| ARCH Venture Fund IX Overage, L.P. Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| ARCH Venture Fund XIII, L.P. Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| ARCH Venture Partners IX, L.P. Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| ARCH Venture Partners IX Overage, L.P. Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| ARCH Venture Partners IX, LLC Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| ARCH Venture Partners XIII, L.P. Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| ARCH Venture Partners XIII, LLC Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| Keith Crandell Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| Clinton Bybee Common Stock par value $0.0001 per share | 5.7 | 1,820,634 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| Robert Nelsen Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| Kristina Burow Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| Steven Gillis Common Stock par value $0.0001 per share | 17.4 | 5,568,424 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| Paul Berns Common Stock par value $0.0001 per share | 11.7 | 3,747,790 | 11/04/2026 Filed 2026-11-10 | SCHEDULE 13G/AAmendment 5 | Open filing 0001012975-26-001025 Dispute this row |
| Foresite Capital Fund IV, L.P. Common Stock, par value $0.0001 | 0.0 | 0.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001104659-26-097073 Dispute this row |
| Foresite Capital Management IV, LLC Common Stock, par value $0.0001 | 0.0 | 0.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001104659-26-097073 Dispute this row |
| Foresite Capital Fund V, L.P. Common Stock, par value $0.0001 | 1.9 | 476,386.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001104659-26-097073 Dispute this row |
| Foresite Capital Management V, LLC Common Stock, par value $0.0001 | 1.9 | 476,386.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001104659-26-097073 Dispute this row |
| Foresite Capital Opportunity Fund V, L.P. Common Stock, par value $0.0001 | 0.7 | 176,942.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001104659-26-097073 Dispute this row |
| Foresite Capital Opportunity Management V, LLC Common Stock, par value $0.0001 | 0.7 | 176,942.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001104659-26-097073 Dispute this row |
| James B. Tananbaum Common Stock, par value $0.0001 | 2.7 | 653,328.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001104659-26-097073 Dispute this row |
| Innovative Cellular Therapeutics Holdings Limited Common Stock, par value $0.0001 | 12.3 | 3,000,000 | 05/18/2026 Filed 2026-06-18 | SCHEDULE 13G/AAmendment 1 | Open filing 0001140361-26-025769 Dispute this row |
| ARCH Venture Fund IX, L.P. Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| ARCH Venture Fund IX Overage, L.P. Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| ARCH Venture Fund XIII, L.P. Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| ARCH Venture Partners IX, L.P. Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| ARCH Venture Partners IX Overage, L.P. Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| ARCH Venture Partners IX, LLC Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| ARCH Venture Partners XIII, L.P. Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| ARCH Venture Partners XIII, LLC Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| Keith Crandell Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| Clinton Bybee Common Stock par value $0.0001 per share | 7.8 | 1,820,634 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| Robert Nelsen Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| Kristina Burow Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| Steven Gillis Common Stock par value $0.0001 per share | 13.9 | 3,247,162 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| Paul Berns Common Stock par value $0.0001 per share | 6.1 | 1,426,528 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001012975-26-000439 Dispute this row |
| MWG Caph Ltd Common Stock, $0.0001 par value per share | 4.3 | 1,008,116 | 03/31/2026 Filed 2026-05-11 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-216076 Dispute this row |
| Milky Way Investments Group Ltd. Common Stock, $0.0001 par value per share | 4.3 | 1,008,116 | 03/31/2026 Filed 2026-05-11 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-216076 Dispute this row |
| Explore Investments LLC Common Stock, par value $0.0001 per share | 6.6 | 1,529,054.00 | 03/31/2026 Filed 2026-05-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0001168404-26-000021 Dispute this row |
| Jeffrey P. Bezos Common Stock, par value $0.0001 per share | 6.6 | 1,529,054.00 | 03/31/2026 Filed 2026-05-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0001168404-26-000021 Dispute this row |
| EULER FUND, L.P. Common Stock | 6.71 | 1,426,528 | 03/06/2026 Filed 2026-04-21 | SCHEDULE 13G | Open filing 0001193125-26-165277 Dispute this row |
| Euler Managers Limited Common Stock | 6.71 | 1,426,528 | 03/06/2026 Filed 2026-04-21 | SCHEDULE 13G | Open filing 0001193125-26-165277 Dispute this row |
| Antonis Indianos Common Stock | 6.71 | 1,426,528 | 03/06/2026 Filed 2026-04-21 | SCHEDULE 13G | Open filing 0001193125-26-165277 Dispute this row |
| Innovative Cellular Therapeutics Holdings Ltd Common Stock, par value $0.0001 | 9.8 | 1,900,000 | 11/06/2025 Filed 2025-11-13 | SCHEDULE 13G | Open filing 0001140361-25-042006 Dispute this row |
| Foresite Capital Fund IV, L.P. Common Stock, par value $0.0001 | 4.2 | 800,339.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112479 Dispute this row |
| Foresite Capital Management IV, LLC Common Stock, par value $0.0001 | 4.2 | 800,339.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112479 Dispute this row |
| Foresite Capital Fund V, L.P. Common Stock, par value $0.0001 | 2.5 | 477,078.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112479 Dispute this row |
| Foresite Capital Management V, LLC Common Stock, par value $0.0001 | 2.5 | 477,078.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112479 Dispute this row |
| Foresite Capital Opportunity Fund V, L.P. Common Stock, par value $0.0001 | 0.9 | 177,199.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112479 Dispute this row |
| Foresite Capital Opportunity Management V, LLC Common Stock, par value $0.0001 | 0.9 | 177,199.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112479 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,540,664 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 17,857 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 166,957 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 262,403 |
Filings made before the SEC required XML are listed, not extracted.